Angiomax bivalirudin: Phase IIIb/IV data

Previously reported results from the double-blind, international Phase IIIb/IV REPLACE-2 trial in 6,010 patients showed that Angiomax treatment was non-inferior to heparin plus GPIIb/IIIa inhibitors ...